Biomarkers and subtypes of breast cancer

Breast cancer is not a single disease. Clinically, breast cancer has been known to have distinct prognosis and response to chemotherapies based on the immunohistochemical (IHC) subtypes [e.g., estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2)] (1,2). hormone receptor (HR)-positive (ER and/or PgR-positive)/HER2-negative breast cancers have a good response to hormone therapy and favourable prognosis. HER2-positive and triple-negative (TN: ER, PgR and HER2-negative) breast cancers have poor baseline prognosis, and good response to HER2 targeted therapy and chemotherapy, respectively. In 2000, molecular subtypes (luminal A, luminal B, HER2 enriched, and basal) in breast cancer were reported (3). mRNA expression patterns in a
set of 65 surgical samples of human breast cancers provided a distinct molecular subtype of each cancer (3). Tumor grade divides HR-positive/HER2-negative tumors into luminal A and B. This discrimination serves to determine the indication of chemotherapy. Gene expression patterns in HR-positive/HER2-negative tumors have been used to improve the genomic markers that may have better predictive power over classical pathological biomarkers (4). On the other hand, an additional clinical value in HER2-positive or TN subtypes is small due to close resemblance to IHC ER, PgR and HER2. Many of these breast cancer subtypes represent biologically distinct disease entities, indicating that each subtype has a distinct prognosis and response to chemotherapy (1,2). These observations lead to the theory that each subtype should have a distinct biomarker (5). Almost twenty years have elapsed since the molecular subtypes were established by Dr. Perou (3); but, how many additional next-generation biomarkers after IHC ER, PgR and HER2 have been available in routine clinical use for early-stage breast cancers in the adjuvant setting?

It takes a long time to introduce a biomarker into daily clinic, due to the lack of consistent evidence, inadequate validation of the biomarker, inadequate evidence of clinical significance, operational barriers to clinical implementation, and inadequate evidence of operational effectiveness or impact in clinical care (6). A biomarker refers to a measurable variable that is associated with the cancer outcome. There is a giant confusion regarding the distinction between a predictive and a prognostic biomarker (7). A prognostic biomarker informs about a likely cancer outcome (e.g., cancer recurrence, cancer progression, and death) impartial of treatment received. If a biomarker is prognostic and therapy is efficacious, the therapeutic benefit is similar for both biomarker-positive and biomarker-negative patients; though the biomarker will nonetheless be associated with a differential outcome, depending on whether it is present or absent. On the other hand, a biomarker is predictive if the therapeutic effect is unique for biomarker-positive patients compared to biomarker-negative patients. In this review, we describe biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer taking prognostic and predictive response to chemotherapy into consideration.

First-generation genomic signatures

Several first-generation genomic signatures highly associated with cell cycle and proliferation have been described for HR-positive/HER2-negative and node-negative breast cancer. Two of these (the 21-gene recurrence score: Oncotype DX, Genomic Health and the 70-gene signature: MammaPrint, Agendia Inc.) were tested by prospective randomized and controlled trials to assess their ability to predict prognosis and chemotherapy response. They are now increasingly used in clinical practice. An encouraging finding is that first-generation genomic signatures showed similar overall performance despite the limited overlap of genes (8). Several common features of TN and HER2-positive tumors had excessive expression of tumor-differentiation genes, together with numerous cell-cycle and proliferation genes (9). In contrast, the HR-positive combined luminal A and luminal B subtypes were not homogeneous (3). Since HR status and histologic grade are predictors of prognosis and response to chemotherapy or even endocrine therapy, and those features are associated with large scale gene expression differences, the first-generation genomic signatures invariably included many genes that capture the clinical phenotype (i.e., HR status and histologic grade) (10). Another critical and consistent finding in the field of genomic prognostic markers is the tumor size and nodal status. Although these have strong prognostic power, they have no powerful gene signatures inherently associated with them. In almost all research, these anatomical pathological variables continue to be statistically significant and independent predictors of prognosis (9,11,12). However, neither tumor size nor nodal status has a strong and consistent association with therapeutic sensitivity (i.e., probability and quantity of response to therapy).

The 70-gene signature has been developed using cDNA microarray analysis on primary breast cancer samples of 117 patients, which applied supervised classification to identify a gene expression signature predictive of breast cancer prognosis (13). The phase 3 randomized MINDACT (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy) study, including 6,693 patients with early-stage breast cancer, aimed to provide prospective evidence of the clinical benefits of adding the 70-gene signature to classical clinical-pathological variables in choosing patients for adjuvant chemotherapy. It showed that approximately 46% of breast cancer patients with high clinical risk might not need chemotherapy (14). Based on the results of the MINDACT study, ASCO guidelines were updated, stating that the 70-gene signature can be used for patients at high clinical risk to decide whether to withhold adjuvant chemotherapy. This method can help identify a good-prognosis population,
who would get limited benefit from chemotherapy, among HR-positive/HER2-negative and lymph node-negative patients (15). On the other hand, for patients in the low clinical risk category, the 70-gene signature does not have clinical benefits because they did not benefit from chemotherapy, irrespective of the risk group.

Another genomic assay, the 21-gene recurrence score, exemplifies the candidate-gene approach to predict the outcome. It measures the expression of ER and HER2, as well as that of ER-regulated transcripts and several proliferation-related genes, by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) (11). The 21-gene recurrence score measures these variables into a recurrence score, which can be used as a continuous variable to predict the probability of recurrence in ten years and to group patients into low, intermediate, and high risk groups (11). Patients who had HR-positive/HER2-negative and lymph node-negative breast cancer with a recurrence score of 11–25 were randomized to receive hormone therapy alone or in combination with chemotherapy (16). For a recurrence score of <11, patients received hormone therapy, and for a recurrence score of >25, patients received a combination therapy. For a patient with a recurrence score of <11, the 5-year disease-free survival (DFS) was 93.8% [95% confidence interval (CI), 92.4 to 94.9] and the overall survival (OS) was 98.0% [95% CI, 97.1 to 98.6] (17), indicating clinicians may offer hormone therapy alone. For the patients with intermediate-risk, recurrence score of 11 to 25 had a similar efficacy between adjuvant endocrine therapy and chemo-endocrine therapy (18). For the patients with a high score of 26 to 100, who received adjuvant chemotherapy, the estimated 5-year DFS was 93% better than that expected with endocrine therapy alone (19).

Based on this evidence, NCCN guidelines Version 3.2019 recommends using 21-gene recurrence score for NCCN category “1” disease as a prognostic and a predictive marker (20). There is no other method that is recommended both as a prognostic and a predictive marker in these guidelines (20). If a patient has HER2-positive or TN breast cancer, the physicians should not use the 21-gene recurrence score to make decisions on adjuvant systemic therapy (21).

The role of the first-generation signature for HR-positive/HER2-negative and node-positive breast cancer is another challenging area. Nodal status in breast cancer is a prognostic but not a predictive marker (9). Typically, patients with HR-positive and node-positive breast cancer should be prescribed not only hormone therapy but also chemotherapy, because they have a poor prognosis regardless of the sensitivity to chemotherapy. Albain et al. reported that the 21-gene recurrence score is prognostic for hormone-treated node-positive patients and predicted a significant benefit of chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil in breast cancers with a high recurrence score in the retrospective data set of 367 patients with breast cancer (22). Stemmer et al. showed the 5-year DFS of patients treated with N1 (1–3 positive lymph nodes) with a recurrence score ≤18, who received hormone therapy alone, to be 2.7% (95% CI, 1.4–5.1%) in the retrospective analysis of a prospectively designed study (23). The prospective phase 3 PlanB trial showed that the 21-gene recurrence score is prognostic for hormone-treated node-positive patients and their 5-year DFS with a recurrence score ≤11 is 94.4% (95% CI, 89.5–99.3%) (24). A phase 3, randomized clinical trial, RxPONDER, to assess the significance of chemotherapy for patients with N1 and recurrence score ≤25 is in progress (ClinicalTrials.gov Identifier: NCT01272037). This trial should provide evidence if the 21-gene recurrence score can predict the efficacy of chemotherapy for patients with N1 and HR-positive/HER2-negative breast cancers. NCCN guidelines v3.2019 states that multigene assays are prognostic, but not predictive, for patients with pN1. We are looking ahead to the consequences of phase 3 RxPONDER trial.

In summary, prospective randomized controlled trials for first-generation signatures, especially the 70-gene signature and the 21-gene recurrence score have been conducted and had met the primary endpoint that HR-positive/HER2-negative and node-negative patients with intermediate-risk can safely skip unnecessary chemotherapy. The node-positive setting is being tested for its predictive value for the multigene assay in a prospective randomized phase 3 trial. These assays will be more frequently used in the future.

Residual disease after neoadjuvant chemotherapy

Neoadjuvant chemotherapy is the standard therapy for locally advanced breast cancers and an alternative option for primary operable breast cancers. Neoadjuvant and adjuvant chemotherapy should clinically have a similar effect on the clinical outcomes, including DFS and OS (25). In one particular trial, there was no significant difference in DFS and OS (P value =0.99 and 0.83, respectively) among patients in the neoadjuvant and adjuvant chemotherapy-treated groups. Most patients were treated pre-operatively

© Chinese Clinical Oncology. All rights reserved.
before undergoing lumpectomy and radiation therapy post-operatively (67.8% versus 59.8%, respectively) (25). One purpose of the neoadjuvant chemotherapy is to be able to perform lumpectomy for cosmetic reasons and to have better clinical outcomes like a total mastectomy. Another purpose is to get clinical information on the response to therapies and provide additional therapies to improve clinical outcomes. Pathological complete response (pCR) after neoadjuvant chemotherapy is associated with long-term survival and has been adopted as the primary endpoint for neoadjuvant trials (25,26). Cortazar et al. reported the predictive value for survival by pCR after neoadjuvant chemotherapy (27). The prognostic value is the greatest in HER2-positive and TN subtypes (27), indicating that neoadjuvant chemotherapy provides an chance to observe the efficacy of a selected chemotherapy regimen directly. Patients with residual breast cancer after neoadjuvant chemotherapy are at a high-risk of recurrence of metastases, which make these patients ideal applicants for clinical trials. Two clinical trials, CREATE-X (28) and KATHERINE (29), have shown improved breast cancer outcomes with post-operative capecitabine and ado-trastuzumab emtansine treatment for patients who had either TN or HER2-positive breast cancer, respectively, who had residual cancer after neoadjuvant chemotherapy. Administering the additional agent for HER2-positive or TN patients with residual disease after neoadjuvant treatments may be a new framework to maximize a chance of survival (30).

In HR-positive/HER2-negative cancers, the clinical significance of pCR after neoadjuvant chemotherapy is not verified. Pooled analysis showed pCR was positively associated with event-free survival (HR 0.49, 95% CI, 0.33–0.71) and OS (0.43, 0.23–0.71), weaker than HER2-positive and TN breast cancers (27). As the adjuvant treatment, hormone therapies are prescribed to the majority of HR-positive patients. The correlation between pCR and survival is more complicated in HER2-positive and TN patients, because of the influence on hormone therapy, as showing in the following “Tumor-infiltrating lymphocytes” section.

Residual cancer burden (RCB) score that is measured as a continuous value combining pathologic measurements of the primary tumor (cellularity and size) and metastatic lymph node (size and number) may be a more powerful predictor than residual cancer after neoadjuvant chemotherapy (31). RCB can be prognostic for long-term survival after neoadjuvant chemotherapy not only in HER2-positive and TN breast cancers but also in the HR-positive/HER2-negative subtype (32).

**Tumor-infiltrating lymphocytes (TILs)**

There are no diagnostic multigene assays for HER2-positive and TN breast cancers. There is only classical clinical and pathological information (tumor size, nodal or distant metastatic status) for the decision making in the adjuvant setting in daily clinic. The extent of TILs by the assessment of hematoxylin and eosin (H&E)-stained tumor specimens is known to provide prognostic data, particularly in HER2-positive and TN breast cancers (33-35), but not in the HR-positive subtype, in the adjuvant setting. Loi et al. reported that a 10% increase in the stromal TILs is associated with a 15% reduced risk of recurrence (P value =0.025) and a 17% reduced risk of death in ER-negative/HER2-negative breast cancers, irrespective of the chemotherapy regimen (33). Similarly, 10% increased stromal TILs is associated with a 14% reduced risk of relapse or death (P value =0.02), an 18% reduced risk of distant relapse (P value =0.04), and a 19% of death (P value =0.01) in patients with TN breast cancer (34). In HER2-positive breast cancers, each 10% increase in TILs was significantly decreased recurrence in patients who received trastuzumab containing regimen (35). Furthermore, core needle biopsies from more than 3,000 breast cancer patients, before the treatment, have been evaluated to understand the predictive value of immune markers as a response to neoadjuvant chemotherapy (36). In a pooled analysis, the presence of higher TILs in pre-treated tumors was associated with favourable pCR rate to neoadjuvant chemotherapy (OR 3.93, 95% CI, 3.26–4.73) (36). The more, TILs expected higher pCR rates in TN (OR 2.49, 95% CI, 1.61–3.83) and HER2-positive (OR 5.05, 95% CI, 2.86–8.92), not in HR-positive (OR 6.21, 95% CI, 0.86–4.51) breast cancers (36). Similar analyses have reported that the higher levels of stromal TILs expected pCR (P value <0.001) in HER2-positive and TN breast cancers (37). Trastuzumab and pertuzumab containing regimen in HER2-positive breast cancers were also evaluated, where the high TIL levels in pre-treated tumors were significantly predictive of pCR in HER2-positive breast cancer (38). In summary, increased TILs can be a predictor of both response to chemotherapy and prognosis after chemotherapy for patients with HER2-positive and TN breast cancers, but not HR-positive breast cancers.

Association between immune functions and HR-positive breast cancer is another interesting topic. Although chemotherapy may be prescribed based on the clinical, pathological, and genomic risk, hormone therapy may
be given to the majority of the patients with HR-positive invasive breast cancer, regardless of the clinical and pathological risk. Even if patients with HR-positive breast cancer achieve pCR after neoadjuvant chemotherapy, indicating they have a good response to chemotherapy, pCR cannot be an indicator of favorable prognosis after surgery. Prediction of prognosis in HR-positive breast cancers treated with hormone therapy should take into consideration the response not only to chemotherapy but also to hormone therapies. Dunbier et al. showed that a higher expression of immune-associated genes such as SLAMF8 and TNF as well as TILs is associated with a poor response to hormone therapies (P value <0.001) (39).

So far, we know that TILs cannot be used to either withhold or provide chemotherapy in the TN subtype or trastuzumab therapy in the HER2-positive subtype, because of the absence of standardized guidelines and limited evidence concerning reproducibility and clinical validity (40). A group of experts for TILs evaluation (the International TIL Working Group), reported recommendations to improve the consistency of TILs scoring and detailed suggestions for annotating TILs (41); however, it is not widely used in daily clinic. Kochi et al. reported the genomic signature related to TILs could be prognostic and potentially predictive as a response to chemotherapy in some breast cancer subtypes to overcome the low reproducibility of evaluations of TILs (42). The measurement of TILs by digital image analysis and machine learning algorithms with artificial intelligence might be useful for standardization of assessment for TILs in the future.

Conclusions

The improvement of tumor biomarkers ready for clinical use is a long process. A good biomarker should be a predictor of not only prognosis but also the response to therapies. Any new scientific intervention can be adopted into clinical practice only in the putting of level 1 evidence, and though costly, such evidence is provided in a prospective randomized clinical trial. Majority of the evidence to change the guidelines have come from the prospective randomized phase 3 trials. Simon et al. advocated that “prospective-retrospective” designs and archived samples from datasets with high-quality might be more efficient (43). In the future, clinical trials with a more efficient design are needed.

For HR-positive/HER2-negative subtype, only two biomarkers, the 21-gene recurrence score and the 70-gene signature, have been tested in prospective randomized clinical trials (14,17,18). There are no diagnostic multigene assays for HER2-positive and TN breast cancers. TILs have been assessed to have a predictive value for prognosis and response to chemotherapy from the retrospective analyses. So far, TILs cannot be used to either withhold or provide chemotherapy based on the absence of standardized evaluation guidelines and confirmed information for HER2-positive and TN breast cancers. To overcome the low reproducibility of evaluations of TILs, gene signatures or digital image analysis and machine learning algorithms with artificial intelligence may be useful for standardization of assessment for TILs in the future.

Acknowledgments

We would like to thank Editage (www.editage.com) for English language editing.

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Yutaka Yamamoto and Takayuki Ueno) for the series “Neoadjuvant/Adjuvant Treatment for Early Breast Cancer” published in Chinese Clinical Oncology. The article was sent for external peer review organized by the Guest Editors and the editorial office.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cco.2020.01.06). This series “Neoadjuvant/Adjuvant Treatment for Early Breast Cancer” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with
the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


Cite this article as: Iwamoto T, Kajiwara Y, Zhu Y, Iha S. Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. Chin Clin Oncol 2020;9(3):27. doi: 10.21037/cco.2020.01.06